The European Medicines Agency has recommended Fruzaqla, Truqap, and Eribulin Baxter for use in the treatment of specific colorectal and breast cancers.
AstraZeneca and Daiichi Sankyo s BLA for Datopotamab Deruxtecan Accepted by FDA for Advanced Breast Cancer Treatment news.europawire.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news.europawire.eu Daily Mail and Mail on Sunday newspapers.
Simulation models indicate that breast cancer screening and treatment were associated with a 58% reduction in mortality, based on data collected between 1975 and 2019.
(Reuters) -Gilead Sciences said on Monday its drug, Trodelvy, failed to significantly improve survival for previously treated patients with advanced non-small cell lung cancer (NSCLC) in a late-stage study, sending its shares down more than 10%. The California-based drugmaker was testing Trodelvy, which belongs to a class of treatments known as antibody drug conjugates, in patients with both squamous and non-squamous NSCLC - the most common type of lung cancer. Roughly 230,000 adults in the United States were estimated to be diagnosed with lung cancer in 2023, and NSCLC accounts for 81% of all those diagnoses, according to the American Society of Clinical Oncology.